Mapp Biopharmaceutical
Press Inquiries
  • About Us
  • Product Development
  • News
    • In the News
    • Press Releases
  • Publications
  • Job Openings
  • Expanded Access Policy
  • Contact Us

New human trials for novel antibody offer hope for immediate protection against deadly Nipah

by Mapp Admin | Jul 3, 2024 | Press Releases

New human trials for novel antibody offer hope for immediate protection against deadly Nipah   3 July 2024; OSLO; CALIFORNIA; Twenty-five years after the first human outbreak of Nipah virus, a novel Nipah monoclonal antibody—which could offer people at risk of...

read more

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

by Mapp Admin | May 15, 2024 | Press Releases

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...

read more

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

by Mapp Admin | Oct 27, 2022 | Press Releases

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease           To further enhance preparedness against health security threats, BARDA is extending a partnership with Mapp...

read more
ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus

ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus

by Mapp Admin | Oct 4, 2022 | Press Releases

ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus     The Administration for Strategic Preparedness and Response (ASPR) today announced a $109.8 million contract with Mapp Biopharmaceutical Inc., for the advanced...

read more
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

by Mapp Admin | Jan 13, 2021 | Press Releases

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin...

read more
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

by Mapp Admin | Jun 11, 2019 | Press Releases

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure June 11, 2019 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and...

read more
Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses

Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses

by Mapp Admin | Jan 11, 2019 | Press Releases

Public Release

read more
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure

MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure

by Mapp Admin | Sep 28, 2018 | Press Releases

MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for...

read more

Archives

  • July 2024
  • May 2024
  • October 2022
  • January 2021
  • June 2019
  • January 2019
  • September 2018

Categories

  • Press Releases

Recent News

New human trials for novel antibody offer hope for immediate protection against deadly Nipah

Jul 3, 2024

New human trials for novel antibody offer hope for immediate protection against deadly Nipah   3 July 2024; OSLO; CALIFORNIA; Twenty-five years after the first human outbreak of Nipah virus, a novel Nipah monoclonal antibody—which could offer people at risk of...

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease

May 15, 2024

BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...

Additional Information

  • New Clinical Study
  • FCOI Policy
  • Purchase Order Terms and Conditions
  • Know Your Rights: Workplace Discrimination is Illegal
  • Institutional Biosafety Committee (NIH)
  •  Affirmative Action Policy Statement for Protected Veterans and Individuals with Disabilities
Jobs Opportunities

© 2017-2024 Mapp Biopharmaceutical. All Rights Reserved.